Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling.
Future Oncol
; 15(11): 1207-1217, 2019 Apr.
Article
em En
| MEDLINE
| ID: mdl-30691297
ABSTRACT
AIM:
Can gene expression profiling be used to identify patients with T1-T2 melanoma at low risk for sentinel lymph node (SLN) positivity? PATIENTS &METHODS:
Bioinformatics modeling determined a population in which a 31-gene expression profile test predicted <5% SLN positivity. Multicenter, prospectively-tested (n = 1421) and retrospective (n = 690) cohorts were used for validation and outcomes, respectively.RESULTS:
Patients 55-64 years and ≥65 years with a class 1A (low-risk) profile had SLN positivity rates of 4.9% and 1.6%. Class 2B (high-risk) patients had SLN positivity rates of 30.8% and 11.9%. Melanoma-specific survival was 99.3% for patients ≥55 years with class 1A, T1-T2 tumors and 55.0% for class 2B, SLN-positive, T1-T2 tumors.CONCLUSION:
The 31-gene expression profile test identifies patients who could potentially avoid SLN biopsy.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Perfilação da Expressão Gênica
/
Transcriptoma
/
Melanoma
Tipo de estudo:
Guideline
/
Prognostic_studies
Limite:
Adolescent
/
Aged80
/
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Estados Unidos